Waldenström's macroglobulinemia medical therapy: Difference between revisions
No edit summary |
No edit summary |
||
| Line 116: | Line 116: | ||
*Plasmapheresis is usually given until chemotherapy starts to work. | *Plasmapheresis is usually given until chemotherapy starts to work. | ||
*Plasmapheresis is combined with chemotherapy to control the disease for a longer period of time. | *Plasmapheresis is combined with chemotherapy to control the disease for a longer period of time. | ||
==References== | ==References== | ||
Revision as of 18:28, 18 November 2015
|
Waldenström's macroglobulinemia Microchapters |
|
Differentiating Waldenström's macroglobulinemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Waldenström's macroglobulinemia medical therapy On the Web |
|
American Roentgen Ray Society Images of Waldenström's macroglobulinemia medical therapy |
|
Directions to Hospitals Treating Waldenström's macroglobulinemia |
|
Risk calculators and risk factors for Waldenström's macroglobulinemia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mirdula Sharma, MBBS [2]
Overview
Risk stratification determines the protocol of management used for Waldenström's macroglobulinemia patients. Watchful waiting is recommended for asymptomatic Waldenström's macroglobulinemia. Symptomatic Waldenström's macroglobulinemia is treated with Rituximab +/- Chemotherapy.[1]
Medical Therapy
There are several different options for treating Waldenström Macroglobulinemia depending on the disease stage.[2]
Asymptomatic/Smoldering Waldenström's macroglobulinemia
Patients who do not have symptoms and whose cancer does not seem to be progressing often do not need treatment. They can be monitored every 3-6 months - a 'wait and watch approach'.[3]
Symptomatic Waldenström's macroglobulinemia
Symptomatic patients with Waldenström Macroglobulinemia are started on chemotherapy depending on the stage.[1]
Initial stage of Waldenström's macroglobulinemia associated with
- Neuropathy,
- Anemia or cytopenias,
- Low-volume nodal involvement, and
- Asymptomatic splenomegaly
Treatment: Single-agent Rituximab therapy
Late stage of Waldenström's macroglobulinemia associated with
- Adenopathy,
- Symptomatic splenomegaly,
- Cytopenias,
- Hyperviscosity syndrome,
- Neuropathy, or
- Constitutional symptoms
| Treatment Regimen | Drugs | Side effects |
|---|---|---|
|
CHOP-R regimen |
|
|
|
Ibrutinib |
|
|
|
Rituximab |
|
|
|
FR regimen |
|
|
|
BDR regimen |
|
|
|
DRC regimen |
|
|
|
CR regimen |
|
|
Hyperviscosity syndrome
- Plasmapheresis is recommended emergent treatment option for patients with Waldenström Macroglobulinemia who develop hyperviscosity symptoms.[1]
- Plasmapheresis temporarily lowers IgM levels by removing some of the abnormal IgM from the blood, which makes the blood thinner.
- However, plasmapheresis does not affect the lymphoma cells.
- Plasmapheresis is usually given until chemotherapy starts to work.
- Plasmapheresis is combined with chemotherapy to control the disease for a longer period of time.
References
- ↑ 1.0 1.1 1.2 1.3 Waldenström's macroglobulinemia. Medscape (2015)http://emedicine.medscape.com/article/2057687-overview Accessed on November 11, 2015
- ↑ Lymphoplasmacytic lymphoma. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/lymphoplasmacytic-lymphoma/?region=ab Accessed on November 6 2015
- ↑ Waldenström's macroglobulinemia. Patient (2015)http://patient.info/doctor/waldenstroms-macroglobulinaemia-pro Accessed on November 10, 2015
- ↑ Waldenström's macroglobulinemia: prognosis and management. Blood Cancer Journal (2015)http://www.nature.com/bcj/journal/v5/n3/full/bcj201528a.html Accessed on November 13, 2015